• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用 STD-NMR 光谱学、计算机模拟研究和抗病毒检测,重新利用美国 FDA 批准的药物对抗 SARS-CoV-2 主要蛋白酶(M)。

Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M) by using STD-NMR spectroscopy, in silico studies and antiviral assays.

机构信息

H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan.

Dr. Panjwani Center for Molecular and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan.

出版信息

Int J Biol Macromol. 2023 Apr 15;234:123540. doi: 10.1016/j.ijbiomac.2023.123540. Epub 2023 Feb 3.

DOI:10.1016/j.ijbiomac.2023.123540
PMID:36740128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9896891/
Abstract

SARS-CoV-2 Main protease (M) is a well-known drug target against SARS-CoV-2 infection. Identification of M inhibitors is vigorously pursued due to its crucial role in viral replication. The present study was aimed to identify M inhibitors via repurposing of US-FDA approved drugs by STD-NMR spectroscopy. In this study, 156 drugs and natural compounds were evaluated against M. Among them, 10 drugs were found to be interacting with M, including diltiazem HCl (1), mefenamic acid (2), losartan potassium (3), mexiletine HCl (4), glaucine HBr (5), trimebutine maleate (6), flurbiprofen (7), amantadine HCl (8), dextromethorphan (9), and lobeline HCl (10) in STD-NMR spectroscopy. Their interactions were compared with three standards (Repurposed anti-viral drugs), dexamethasone, chloroquine phosphate, and remdesivir. Thermal stability of M and dissociation constant (K) of six interacting drugs were also determined using DSF. RMSD plots in MD simulation studies showed the formation of stable protein-ligand complexes. They were further examined for their antiviral activity by plaque reduction assay against SARS-CoV-2, which showed 55-100% reduction in viral plaques. This study demonstrates the importance of drug repurposing against emerging and neglected diseases. This study also exhibits successful application of STD-NMR spectroscopy combined with plaque reduction assay in rapid identification of potential anti-viral agents.

摘要

严重急性呼吸综合征冠状病毒 2 主蛋白酶(M)是针对严重急性呼吸综合征冠状病毒 2 感染的著名药物靶点。由于其在病毒复制中的关键作用,因此积极寻找 M 抑制剂。本研究旨在通过 STD-NMR 光谱法重新利用美国食品和药物管理局批准的药物来鉴定 M 抑制剂。在这项研究中,评估了 156 种药物和天然化合物对 M 的作用。其中,有 10 种药物被发现与 M 相互作用,包括盐酸地尔硫卓(1)、甲芬那酸(2)、洛沙坦钾(3)、盐酸美西律(4)、溴化白屈菜碱(5)、马来酸曲美布汀(6)、氟比洛芬(7)、盐酸金刚烷胺(8)、右美沙芬(9)和盐酸洛贝林(10)。在 STD-NMR 光谱中,比较了它们与三种标准药物(重新利用的抗病毒药物)、地塞米松、磷酸氯喹和瑞德西韦的相互作用。使用 DSF 还测定了 M 的热稳定性和解离常数(K)。MD 模拟研究中的 RMSD 图显示了稳定的蛋白质-配体复合物的形成。通过针对 SARS-CoV-2 的蚀斑减少测定法进一步检查了它们的抗病毒活性,结果显示病毒蚀斑减少了 55-100%。这项研究证明了针对新兴和被忽视疾病的药物再利用的重要性。该研究还展示了 STD-NMR 光谱法与蚀斑减少测定法相结合在快速鉴定潜在抗病毒药物方面的成功应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/6590a5b7efbe/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/dbc93068559d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/5439fba3ef26/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/f5ee1c4c4163/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/3268057556fd/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/ecc828b09a6b/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/6c38fb03ddbe/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/ce0c305cdf48/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/d4575a380f3a/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/6590a5b7efbe/gr9_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/dbc93068559d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/5439fba3ef26/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/f5ee1c4c4163/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/3268057556fd/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/ecc828b09a6b/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/6c38fb03ddbe/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/ce0c305cdf48/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/d4575a380f3a/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad4d/9896891/6590a5b7efbe/gr9_lrg.jpg

相似文献

1
Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M) by using STD-NMR spectroscopy, in silico studies and antiviral assays.利用 STD-NMR 光谱学、计算机模拟研究和抗病毒检测,重新利用美国 FDA 批准的药物对抗 SARS-CoV-2 主要蛋白酶(M)。
Int J Biol Macromol. 2023 Apr 15;234:123540. doi: 10.1016/j.ijbiomac.2023.123540. Epub 2023 Feb 3.
2
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.
3
Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.靶向 SARS-CoV-2 主蛋白酶:一项计算药物再利用研究。
Arch Med Res. 2021 Jan;52(1):38-47. doi: 10.1016/j.arcmed.2020.09.013. Epub 2020 Sep 17.
4
A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.多阶段虚拟筛选 FDA 批准药物揭示 SARS-CoV-2 主蛋白酶潜在抑制剂。
J Biomol Struct Dyn. 2022 Mar;40(5):2327-2338. doi: 10.1080/07391102.2020.1837680. Epub 2020 Oct 23.
5
Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an Drug Repurposing Approach.靶向 SARS-CoV-2 主蛋白酶:药物再利用方法指导下的成功故事。
J Chem Inf Model. 2023 Jun 12;63(11):3601-3613. doi: 10.1021/acs.jcim.3c00282. Epub 2023 May 25.
6
Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system.通过人工智能支持的活性预测系统从美国食品药品监督管理局批准的药物中鉴定严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂
J Biomol Struct Dyn. 2023 Mar;41(5):1767-1775. doi: 10.1080/07391102.2021.2024260. Epub 2022 Jan 5.
7
Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.通过MM/GBSA鉴定沙奎那韦作为二聚体SARS-CoV-2主要蛋白酶的有效抑制剂。
J Mol Model. 2020 Nov 12;26(12):340. doi: 10.1007/s00894-020-04600-4.
8
Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.基于已批准的抗病毒和抗感染药物的计算机药物重定位研究:氨基糖苷类药物作为新型冠状病毒 2 主蛋白酶抑制剂的潜力。
J Infect Public Health. 2021 May;14(5):611-619. doi: 10.1016/j.jiph.2021.01.016. Epub 2021 Feb 9.
9
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
10
Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.HIV-1 蛋白酶抑制剂 - 临床试验药物作为 SARS-CoV-2 主蛋白酶的再利用药物的可能性:分子对接、分子动力学和结合自由能模拟研究。
J Biomol Struct Dyn. 2021 Sep;39(15):5368-5375. doi: 10.1080/07391102.2020.1786459. Epub 2020 Jul 6.

引用本文的文献

1
Sulfonohydrazide as a potential inhibitor of SARS-CoV-2 infection.磺酰肼作为一种潜在的新型冠状病毒感染抑制剂。
Sci Rep. 2025 May 28;15(1):18732. doi: 10.1038/s41598-025-03685-2.
2
Computer-aided drug design for the double-membrane vesicle pore complex inhibitors against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)双膜囊泡孔复合物抑制剂的计算机辅助药物设计
Front Microbiol. 2025 Mar 28;16:1562187. doi: 10.3389/fmicb.2025.1562187. eCollection 2025.
3
Protein to biomaterials: Unraveling the antiviral and proangiogenic activities of Ac-Tβ peptide, a thymosin β4 metabolite, and its implications in peptide-scaffold preparation.
蛋白质到生物材料:揭示胸腺素β4代谢产物Ac-Tβ肽的抗病毒和促血管生成活性及其在肽支架制备中的意义。
Bioact Mater. 2025 Mar 19;49:437-455. doi: 10.1016/j.bioactmat.2025.02.008. eCollection 2025 Jul.
4
Identification of effective synthetic molecules against viral-induced cytokine release syndrome using in silico and in vitro approaches.利用计算机模拟和体外实验方法鉴定抗病毒诱导的细胞因子释放综合征的有效合成分子。
Mol Divers. 2025 Feb 25. doi: 10.1007/s11030-025-11136-3.